BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

 Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor ...

Related Keywords

Italy ,Spain ,Germany ,United States ,Belgium ,Maryland ,Rockville ,Helen Schiltz ,Pan Zheng ,Fosun Pharma ,Martin Devenport ,Exchange Commission ,Drug Administration ,Roche Group ,Pfizer ,Genentech ,Track Designation ,Fast Track Designation ,Chief Medical Officer ,New Technologies ,Private Securities Litigation Reform Act ,Quarterly Report ,